DISCOVER OUR NEWS
TheraPPI closes Pre-Seed Financing and strengthens its Board of Directors with the election of Christopher Meyer as Chairperson
Following non-dilutive financing, TheraPPI closes a Pre-Seed equity round. Christopher Meyer joins the company as Independent Chairperson of the Board
TheraPPI obtains a €300,000 loan from Bpifrance to advance its research programmes and support its growth
TheraPPI obtains a €300,000 loan from Bpifrance to advance its research programmes and support its growth
TheraPPI completes a first closing of Pre-Seed Financing to advance its lead oncology program targeting a novel protein interaction
In addition to non-dilutive financing, TheraPPI completes initial equity financing to develop its lead program targeting ERK/MyD88 interaction
TheraPPI announces publication of preclinical data in Nature Communications, demonstrating the inhibition of ERK/MyD88 interaction as a promising cancer treatment
TheraPPI scientists publish preclinical data in Nature Communications, demonstrating the inhibition of ERK/MyD88 interaction as a promising cancer treatment
TheraPPI Bioscience awarded the French Tech Emergence grant
TheraPPI has been awarded the French Tech Emergence Grant by BPI France in the context of the “Programme France 2030”.
TheraPPI Bioscience awarded reputable French Tech Seed label
The Pouss@LYS consortium has recently given a favorable recommendation on French Tech Seed label to TheraPPI